Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN)

NCT04145440 is registered in ClinicalTrials.gov with HI-Bio, A Biogen Company as lead sponsor.

NCT NCT04145440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04145440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN)
Lead sponsor
HI-Bio, A Biogen Company
Phase
Phase 1/2
Overall status
Completed
Start date
October 15, 2019
Completion date
August 2, 2022
Enrollment
31 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

antipla2r positive, glomerulonephritis, membranous